ArticleKidney international reports2019
Autoantibodies Specific for Galactose-Deficient IgA1 in IgA Vasculitis With Nephritis.
Article in Kidney international reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Evidence-based guidelines for the diagnosis and management of adult-onset IgA vasculitis.Nature reviews. Rheumatology · 2026Guideline
- Infectious triggers in IgA vasculitis in children: current evidence, causal attribution and immunopathogenic mechanisms.Rheumatology international · 2026Review
- Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.Current opinion in rheumatology · 2026Review
- Case report: Sequential complement inhibition and BAFF/APRIL blockade in progressive IgA nephropathy and IgA vasculitis nephritis: a report of two cases.Frontiers in immunology · 2026Article
- Research progress on biomarkers of immunoglobulin a vasculitis nephritis: from classical molecules to multi-omics system analysis.Frontiers in immunology · 2026Review
- Kidney injury and colocalization of complement C3, IgA, and IgG in glomerular immune-complex deposits of patients with IgA nephropathy or IgA vasculitis with nephritis.Kidney international · 2025Article
- Article
- Tonsillectomy in Immunoglobulin A vasculitis with nephritis: case series.CEN case reports · 2025Article
- A case of de novo glomerulonephritis following COVID-19 in a patient with preexistent IgA vasculitis.CEN case reports · 2025Article
- Modern biomarkers in IgA vasculitis with nephritis in children.Central-European journal of immunology · 2025Review
- Insight into the Interplay of Gd-IgA1, HMGB1, RAGE and PCDH1 in IgA Vasculitis (IgAV).International journal of molecular sciences · 2024Article
- IgA Nephropathy: Pleiotropic impact of Epstein-Barr virus infection on immunopathogenesis and racial incidence of the disease.Frontiers in immunology · 2023Review
- Pathophysiology and clinical manifestations of immune complex vasculitides.Frontiers in medicine · 2023Review
- Development of IgA vasculitis with severe glomerulonephritis after COVID-19 vaccination: a case report and literature review.CEN case reports · 2022Review
- Sudden Onset of IgA Vasculitis Affecting Vital Organs in Adult Patients following SARS-CoV-2 Vaccines.Vaccines · 2022Article
- IgA vasculitis with nephritis: update of pathogenesis with clinical implications.Pediatric nephrology (Berlin, Germany) · 2022Review
- IgA vasculitis update: Epidemiology, pathogenesis, and biomarkers.Frontiers in immunology · 2022Review
- IgA Vasculitis with Nephritis in Adults: Histological and Clinical Assessment.Journal of clinical medicine · 2021Article
- IgA vasculitis nephritis in children and adults: one or different entities?Pediatric nephrology (Berlin, Germany) · 2021Review
- An Update on the Current State of Management and Clinical Trials for IgA Nephropathy.Journal of clinical medicine · 2021Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with IgA nephropathy (IgAN) have elevated serum levels of galactose-deficient IgA1 (Gd-IgA1) that are bound by Gd-IgA1-specific autoantibodies in pathogenic immune complexes. Renal biopsy histopathologic features of IgA vasculitis (IgAV) with nephritis (IgAV-N) are similar to those of IgAN. Mucosal infections often are associated with clinical onset and exacerbation in both diseases. We investigated whether patients with IgAV-N share pathogenic characteristics of IgAN.
methodsWe generated IgA1- and IgG-secreting cell lines from Epstein-Barr virus (EBV)-immortalized cells of patients with IgAV without nephritis (IgAV-woN), IgAV-N, and IgAN and from healthy individuals. Sera and cell-culture supernatants were used for analysis of Gd-IgA1 and Gd-IgA1-specific IgG autoantibodies.
resultsIgA1-producing cells from patients with IgAV-N, like cells from patients with IgAN, secreted more Gd-IgA1 than did cells from patients with IgAV-woN or healthy control subjects, in agreement with elevated serum Gd-IgA1 levels in patients with IgAV-N and IgAN. IgA1-producing cells from patients with IgAV-N had altered expression of genes involved in
conclusionSerum levels and cellular production of Gd-IgA1 and Gd-IgA1-specific IgG autoantibodies were elevated in patients with IgAV-N, supporting the hypothesis that IgAV-N and IgAN share pathogenic features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.